Everolimus drug‐eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry

Autor: Bruno García del Blanco, Christophe Bretelle, Santiago Jesús Camacho Freire, Nicolas Delarche, Ramón López Palop, Franck Albert, Javier Zueco Gil, Vicente Mainar Tello, José Francisco Díaz Fernández, Juan Carlos Fernández Guerrero
Rok vydání: 2018
Předmět:
Male
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Population
Coronary Artery Disease
030204 cardiovascular system & hematology
Prosthesis Design
Lesion
03 medical and health sciences
0302 clinical medicine
Risk Factors
Intravascular ultrasound
medicine
Humans
Radiology
Nuclear Medicine and imaging
Everolimus
Prospective Studies
Registries
cardiovascular diseases
030212 general & internal medicine
Myocardial infarction
Angioplasty
Balloon
Coronary
education
Aged
education.field_of_study
medicine.diagnostic_test
business.industry
Stent
Percutaneous coronary intervention
Cardiovascular Agents
Drug-Eluting Stents
General Medicine
Middle Aged
medicine.disease
Surgery
Europe
Treatment Outcome
Drug-eluting stent
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Mace
Zdroj: Catheterization and Cardiovascular Interventions. 92:E493-E501
ISSN: 1522-726X
1522-1946
Popis: Objectives To assess the efficacy and safety of the Xience Prime everolimus-eluting stent (EES) in long coronary lesions in a real-world population. Background Long lesions are considered difficult technically and in terms of achieving successful clinical outcomes. With first generation DES, MACE can be as high as 10% at a short-medium term follow-up. There are a few data available in this subset regarding the use of second generation DES METHODS: A prospective, multicenter registry of consecutive patients (aged 64.8 ± 11.2 years, 77% men and 33% diabetics) in 29 tertiary hospitals with de novo > 24 mm lesions in vessels of 2.25-4 mm was performed. The primary and secondary endpoints were major adverse cardiac events (MACE; cardiac death, myocardial infarction, and target lesion revascularization) and stent thrombosis (ST) at 1, 12, and 24 months. Patients were on dual antiplatelet therapy during 12 months. Results A total of 610 patients with 705 long lesions were included (1.2 per patient). Lesion length was 34.59 ± 11.17 mm and vessel size 2.93 ± 0.41 mm. Stented length was 39.83 ± 14.08 mm (1.4 stents per lesion). Predilatation/postdiltatation was performed in 75 and 33% of the cases, intravascular ultrasound in 15%. The device success rate was 99.1%. MACE and ST rates at 1, 12, and 24-months follow-up were 0.3, 2.1, and 5.4% and 0.2, 0.7, and 1.5%, respectively. Conclusion In this real-world population, the Xience Prime EES performs extremely well in long lesions, with a very low rate of both MACE and ST.
Databáze: OpenAIRE
Externí odkaz: